159 related articles for article (PubMed ID: 35837705)
21. PROMIS Function Scores Are Lower in Patients Who Underwent More Aggressive Local Treatment for Desmoid Tumors.
Newman ET; Lans J; Kim J; Ferrone M; Ready J; Schwab J; Raskin K; Calderon SL
Clin Orthop Relat Res; 2020 Mar; 478(3):563-577. PubMed ID: 31429829
[TBL] [Abstract][Full Text] [Related]
22. Magnetic resonance imaging patterns of tumor response to chemotherapy in desmoid-type fibromatosis.
Zanchetta E; Ciniselli CM; Bardelli A; Colombo C; Stacchiotti S; Baldi GG; Provenzano S; Bertulli R; Bini F; Casale A; Greco FG; Ferrari A; Verderio P; Fiore M; Gronchi A; Casali PG; Morosi C; Palassini E
Cancer Med; 2021 Jul; 10(13):4356-4365. PubMed ID: 34102009
[TBL] [Abstract][Full Text] [Related]
23. Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG).
Kasper B; Gruenwald V; Reichardt P; Bauer S; Rauch G; Limprecht R; Sommer M; Dimitrakopoulou-Strauss A; Pilz L; Haller F; Hohenberger P
Eur J Cancer; 2017 May; 76():60-67. PubMed ID: 28282612
[TBL] [Abstract][Full Text] [Related]
24. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
25. Sorafenib for Advanced and Refractory Desmoid Tumors.
Gounder MM; Mahoney MR; Van Tine BA; Ravi V; Attia S; Deshpande HA; Gupta AA; Milhem MM; Conry RM; Movva S; Pishvaian MJ; Riedel RF; Sabagh T; Tap WD; Horvat N; Basch E; Schwartz LH; Maki RG; Agaram NP; Lefkowitz RA; Mazaheri Y; Yamashita R; Wright JJ; Dueck AC; Schwartz GK
N Engl J Med; 2018 Dec; 379(25):2417-2428. PubMed ID: 30575484
[TBL] [Abstract][Full Text] [Related]
26. Pazopanib therapy for desmoid tumors in adolescent and young adult patients.
Agresta L; Kim H; Turpin BK; Nagarajan R; Plemmons A; Szabo S; Dasgupta R; Sorger JI; Pressey JG
Pediatr Blood Cancer; 2018 Jun; 65(6):e26968. PubMed ID: 29384266
[TBL] [Abstract][Full Text] [Related]
27. Outcome of Primary Desmoid Tumors at All Anatomic Locations Initially Managed with Active Surveillance.
van Houdt WJ; Husson O; Patel A; Jones RL; Smith MJF; Miah AB; Messiou C; Moskovic E; Al-Muderis O; Benson C; Zaidi S; Dunlop A; Strauss DC; Hayes AJ; van der Graaf WTA
Ann Surg Oncol; 2019 Dec; 26(13):4699-4706. PubMed ID: 31531797
[TBL] [Abstract][Full Text] [Related]
28. Current management and recent progress in desmoid tumors.
Zhou MY; Bui NQ; Charville GW; Ghanouni P; Ganjoo KN
Cancer Treat Res Commun; 2022; 31():100562. PubMed ID: 35460976
[TBL] [Abstract][Full Text] [Related]
29. Desmoid fibromatosis: is the current picture changing?
Pandrowala S; Jones RL; Gupta S; Gulia A
Future Oncol; 2021 Sep; 17(25):3397-3408. PubMed ID: 34227399
[TBL] [Abstract][Full Text] [Related]
30. Desmoid-type fibromatosis in children. Clinical features, treatment response, and long-term follow-up.
Fortunati D; Kaplan J; López Martí J; Ponzone A; Innocenti S; Fiscina S; Cacciavillano W; Zubizarreta P; Rose A
Medicina (B Aires); 2020; 80(5):495-504. PubMed ID: 33048794
[TBL] [Abstract][Full Text] [Related]
31. Desmoid with biweekly methotrexate and vinblastine shows similar effects to weekly administration: A phase II clinical trial.
Nishida Y; Hamada S; Urakawa H; Ikuta K; Sakai T; Koike H; Ito K; Emoto R; Ando Y; Matsui S
Cancer Sci; 2020 Nov; 111(11):4187-4194. PubMed ID: 32816351
[TBL] [Abstract][Full Text] [Related]
32. Treatment of Orbital Desmoid-type Fibromatosis With Sorafenib.
Downie EM; Amend CE; Miranda A; Burkat CN
Ophthalmic Plast Reconstr Surg; 2022 Sep-Oct 01; 38(5):e144-e147. PubMed ID: 35470290
[TBL] [Abstract][Full Text] [Related]
33. [Facial infantile aggressive fibromatosis: a frequent localization of an exceptional tumor!].
Bouguila J; Khonsari RH; Zitouni K; Zairi I; Adouani A
Ann Chir Plast Esthet; 2012 Jun; 57(3):304-7. PubMed ID: 20561731
[TBL] [Abstract][Full Text] [Related]
34. Molecular Pathogenesis of Sporadic Desmoid Tumours and Its Implications for Novel Therapies: A Systematised Narrative Review.
McLean TD; Duchi S; Di Bella C
Target Oncol; 2022 May; 17(3):223-252. PubMed ID: 35446005
[TBL] [Abstract][Full Text] [Related]
35. Therapy of desmoid tumors and fibromatosis using vinorelbine.
Weiss AJ; Horowitz S; Lackman RD
Am J Clin Oncol; 1999 Apr; 22(2):193-5. PubMed ID: 10199460
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of apatinib for patients with advanced extremity desmoid fibromatosis: a retrospective study.
Zheng C; Fang J; Wang Y; Zhou Y; Tu C; Min L
J Cancer Res Clin Oncol; 2021 Jul; 147(7):2127-2135. PubMed ID: 33452581
[TBL] [Abstract][Full Text] [Related]
37. Combination chemotherapy with methotrexate and vinblastine for surgically unresectable, aggressive fibromatosis.
Park KH; Choi YJ; Kim KW; Ro KH; Kang CH; Song SH; Park JH
Jpn J Clin Oncol; 2016 Sep; 46(9):845-9. PubMed ID: 27365524
[TBL] [Abstract][Full Text] [Related]
38. Aggressive fibromatosis of the neck treated with a combination of chemotherapy and indomethacin.
Longhi A; Errani C; Battaglia M; Alberghini M; Ferrari S; Mercuri M; Molinari M
Ear Nose Throat J; 2011 Jun; 90(6):E11-5. PubMed ID: 21674455
[TBL] [Abstract][Full Text] [Related]
39. Desmoid tumors: To treat or not to treat, That is the question.
Kasper B; Raut CP; Gronchi A
Cancer; 2020 Dec; 126(24):5213-5221. PubMed ID: 33022074
[TBL] [Abstract][Full Text] [Related]
40. Multimodal treatment of children with unresectable or recurrent desmoid tumors: an 11-year longitudinal observational study.
Lackner H; Urban C; Benesch M; Raith J; Moser A; Sovinz P; Schwinger W; Dornbusch HJ; Triebl-Roth K
J Pediatr Hematol Oncol; 2004 Aug; 26(8):518-22. PubMed ID: 15284591
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
